New T cell therapies for childhood cancers
NGTC - UCL
This study is working on creating special treatments using T cells to help kids with tough-to-treat solid cancers, like certain types of sarcomas and brain tumors, by making these immune cells better at finding and fighting cancer cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University College London NIH-funded |
| Lab location | 1 site (London, United Kingdom) |
| Project ID | NIH-10631014 on NIH RePORTER |
What this research studies
This research focuses on developing advanced T cell therapies specifically designed for treating childhood solid cancers, which are often resistant to current treatments. The approach involves engineering T cells to target and attack cancer cells more effectively, overcoming challenges such as tumor heterogeneity and a hostile tumor microenvironment. By studying primary tumors, the research aims to identify new targets for therapy and improve T cell function in these difficult-to-treat cancers. The project is structured into interconnected work packages, initially targeting pediatric sarcomas and brain tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with solid tumors, particularly sarcomas and brain tumors, who have not responded to existing therapies.
Not a fit: Patients with hematologic malignancies or those whose tumors do not fall within the targeted categories may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for children suffering from solid tumors.
How similar studies have performed: Previous research in engineered T cell therapies for adult cancers has shown promising results, suggesting potential for success in pediatric applications as well.
Where this research is happening
London, United Kingdom
- University College London — London, United Kingdom (Active)
Researchers
- Principal investigator: Pule, Martin — University College London
- Study coordinator: Pule, Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.